Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Trileptal

Known as: Novartis brand of oxcarbazepine 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
A prospective non-randomized non-controlled multicenter trial has been conducted. The trial included 254 children, aged from 11… Expand
Is this relevant?
2009
2009
  • B J Steinhoff
  • Expert review of clinical pharmacology
  • 2009
  • Corpus ID: 44701286
Oxcarbazepine (OXC) is a 10-keto-analogue of carbamazepine, which was developed and labeled as a follow-up antiepileptic drug… Expand
Is this relevant?
2006
2006
AIM Pharmacoeconomics comprises a system of relatively new methods that inform policy makers about the costs and benefits of… Expand
Is this relevant?
2005
2005
[reaction: see text] A new route to oxcarbazepine (Trileptal), the most widely prescribed antiepileptic drug, starting from… Expand
Is this relevant?
Review
2004
Review
2004
Oxcarbazepine (OXC, Trileptal) is a modern antiepileptic drug (AED) used as both monotherapy and adjunctive therapy for the… Expand
Is this relevant?
2001
2001
OBJECTIVE To evaluate the efficacy and safety of oxcarbazepine (OXC) as monotherapy for patients with uncontrolled partial… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2001
2001
A high throughput preparation method for the determination of trileptal (oxcarbazepine, OXC) and its mono (MHD) and dihydroxy… Expand
Is this relevant?
2000
2000
ZusammenfassungOxcarbazepin (10,11-dihydro-10-oxo-5H-dibenz-[b,f]azepin-5-carboxamid; OXC, Handelsname Trileptal®) ist ein neues… Expand
Is this relevant?
1994
1994
Oxcarbazepine (OCBZ, Trileptal) and its main human monohydroxy metabolite (MHD) protected mice and rats against generalized tonic… Expand
Is this relevant?
1990
1990
The anti-epileptic activity of oxcarbazepine (OXC) was compared with that of carbamazepine (CBZ) and the primary active… Expand
Is this relevant?